Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18163524 | 1.00 | SYK (0.54) | SYKATMMAPTPPARACTSK | |
| SCHEMBL16823456 | 1.00 | SYK (0.54) | SYKATMMAPTPPARACTSK | |
| SCHEMBL18143168 | 1.00 | SYK (0.54) | SYKATMMAPTPPARACTSK | |
| SCHEMBL16823454 | 1.00 | SYK (0.54) | SYKATMMAPTPPARACTSK | |
| SCHEMBL18157219 | 0.90 | ATM (0.53) | SYKATMCTSKCTSSCTSL | |
| SCHEMBL19812740 | 0.82 | SYK (0.61) | SYKATMMAPTPPARACTSK | |
| SCHEMBL16824022 | 0.82 | SYK (0.61) | SYKATMMAPTPPARACTSK | |
| SCHEMBL18143207 | 0.82 | SYK (0.61) | SYKATMMAPTPPARACTSK | |
| SCHEMBL16824023 | 0.82 | SYK (0.61) | SYKATMMAPTPPARACTSK | |
| SCHEMBL6381541 | 0.81 | SYK (0.60) | SYKATMMAPTPPARACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221146-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | SYK 2404/4885ATM 4865/4885MAPT 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.